Biogen’s applications for the higher dose regimen of spinal muscular atrophy (SMA) drug Spinraza are now under review in the US and Europe.

The FDA has granted orphan drug designation (ODD) to Zai Lab’s ZL-1310, aimed at treating small cell lung cancer (SCLC).

Emergent Biosolutions (Gaithersburg, US) has purchased US and Canadian rights to Kloxxado, adding to its opioid overdose ...

Disc Medicine finalised the pivotal Phase III trial design of bitopertin in erythropoietic protoporphyria (EPP) with the FDA ...

The FDA reported that six patients died after being injected with Teva’s Copaxone or Sandoz’s Glatopa. The US Food and Drug ...

Cellipont and Secretome Therapeutics are set to enter a collaboration for the manufacturing of the latter’s cellular therapy, ...

Viralgen and Axovia are set to form a partnership to progress the development and manufacturing of gene therapy for retinal ...

Catalent, a global contract development and manufacturing organization (CDMO), has been recognized with two awards in the ...

Tagrisso and Imfinzi are projected to generate global sales of $8bn and $7bn, respectively, by 2030, according to GlobalData.

The funding of up to £500,000 is provided by LifeArc, a medical research charity, to support the development of Glox’s ...

Panellists at the World Economic Forum 2025 Davos meeting discussed how artificial intelligence (AI) could help close the gap ...

The FDA placed a clinical hold on two Atara assets, following an inspection at a third-party site that also led to a CRL for ...